Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles

 
• By David Wild
Nimbus Therapeutics Closed One of the Largest Single-Asset Deals in Biotech History • Source: Shutterstock

More from Deal-Making

More from In Vivo